Multidimensional effects of sertraline in social anxiety disorder

Kathryn M. Connor, Jonathan R T Davidson, Henry Chung, Ruoyong Yang, Cathryn M. Clary

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Clinical trials of social anxiety disorder (SAD) have largely focused on the effect of treatment on symptoms of fear and avoidance, while neglecting the third clinically relevant dimension, physiological arousal. Data were combined from two previously reported placebo-controlled trials of sertraline in the treatment of moderate-to-severe generalized SAD. Efficacy was evaluated using the Brief Social Phobia Scale (BSPS). Three hundred forty-six subjects were randomized to 12-13 weeks of treatment with sertraline and 273 subjects to placebo. Following treatment, significant improvement was noted in favor of sertraline on the full BSPS (P<.001), as well as on each of the individual BSPS subscales: fear (P=.001); avoidance (P<.0001); and physiological arousal (P<.0001). Of the physiological symptoms assessed, the treatment advantage with sertraline was maintained for blushing (P<.003) and palpitations (P<.03), but not for trembling and sweating. These results confirm the efficacy of treatment with a selective serotonin reuptake inhibitor (SSRI), sertraline, across the spectrum of fear, avoidance, and physiological arousal in generalized SAD (GSAD). Among common physiological symptoms in this population, blushing and palpitations appear more treatment responsive than trembling and sweating to acute treatment with sertraline.

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalDepression and Anxiety
Volume23
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Sertraline
Blushing
Arousal
Fear
Sweating
Therapeutics
Placebos
Serotonin Uptake Inhibitors
Social Phobia
Clinical Trials
Population

Keywords

  • Blushing
  • Hyperhidrosis
  • Phobic disorders
  • Randomized controlled trial
  • Serotonin reuptake inhibitors
  • Sertraline
  • Social anxiety disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Multidimensional effects of sertraline in social anxiety disorder. / Connor, Kathryn M.; Davidson, Jonathan R T; Chung, Henry; Yang, Ruoyong; Clary, Cathryn M.

In: Depression and Anxiety, Vol. 23, No. 1, 2006, p. 6-10.

Research output: Contribution to journalArticle

Connor, Kathryn M. ; Davidson, Jonathan R T ; Chung, Henry ; Yang, Ruoyong ; Clary, Cathryn M. / Multidimensional effects of sertraline in social anxiety disorder. In: Depression and Anxiety. 2006 ; Vol. 23, No. 1. pp. 6-10.
@article{a9102f4ba1e343e98eba29aa388fb66a,
title = "Multidimensional effects of sertraline in social anxiety disorder",
abstract = "Clinical trials of social anxiety disorder (SAD) have largely focused on the effect of treatment on symptoms of fear and avoidance, while neglecting the third clinically relevant dimension, physiological arousal. Data were combined from two previously reported placebo-controlled trials of sertraline in the treatment of moderate-to-severe generalized SAD. Efficacy was evaluated using the Brief Social Phobia Scale (BSPS). Three hundred forty-six subjects were randomized to 12-13 weeks of treatment with sertraline and 273 subjects to placebo. Following treatment, significant improvement was noted in favor of sertraline on the full BSPS (P<.001), as well as on each of the individual BSPS subscales: fear (P=.001); avoidance (P<.0001); and physiological arousal (P<.0001). Of the physiological symptoms assessed, the treatment advantage with sertraline was maintained for blushing (P<.003) and palpitations (P<.03), but not for trembling and sweating. These results confirm the efficacy of treatment with a selective serotonin reuptake inhibitor (SSRI), sertraline, across the spectrum of fear, avoidance, and physiological arousal in generalized SAD (GSAD). Among common physiological symptoms in this population, blushing and palpitations appear more treatment responsive than trembling and sweating to acute treatment with sertraline.",
keywords = "Blushing, Hyperhidrosis, Phobic disorders, Randomized controlled trial, Serotonin reuptake inhibitors, Sertraline, Social anxiety disorder",
author = "Connor, {Kathryn M.} and Davidson, {Jonathan R T} and Henry Chung and Ruoyong Yang and Clary, {Cathryn M.}",
year = "2006",
doi = "10.1002/da.20086",
language = "English (US)",
volume = "23",
pages = "6--10",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Multidimensional effects of sertraline in social anxiety disorder

AU - Connor, Kathryn M.

AU - Davidson, Jonathan R T

AU - Chung, Henry

AU - Yang, Ruoyong

AU - Clary, Cathryn M.

PY - 2006

Y1 - 2006

N2 - Clinical trials of social anxiety disorder (SAD) have largely focused on the effect of treatment on symptoms of fear and avoidance, while neglecting the third clinically relevant dimension, physiological arousal. Data were combined from two previously reported placebo-controlled trials of sertraline in the treatment of moderate-to-severe generalized SAD. Efficacy was evaluated using the Brief Social Phobia Scale (BSPS). Three hundred forty-six subjects were randomized to 12-13 weeks of treatment with sertraline and 273 subjects to placebo. Following treatment, significant improvement was noted in favor of sertraline on the full BSPS (P<.001), as well as on each of the individual BSPS subscales: fear (P=.001); avoidance (P<.0001); and physiological arousal (P<.0001). Of the physiological symptoms assessed, the treatment advantage with sertraline was maintained for blushing (P<.003) and palpitations (P<.03), but not for trembling and sweating. These results confirm the efficacy of treatment with a selective serotonin reuptake inhibitor (SSRI), sertraline, across the spectrum of fear, avoidance, and physiological arousal in generalized SAD (GSAD). Among common physiological symptoms in this population, blushing and palpitations appear more treatment responsive than trembling and sweating to acute treatment with sertraline.

AB - Clinical trials of social anxiety disorder (SAD) have largely focused on the effect of treatment on symptoms of fear and avoidance, while neglecting the third clinically relevant dimension, physiological arousal. Data were combined from two previously reported placebo-controlled trials of sertraline in the treatment of moderate-to-severe generalized SAD. Efficacy was evaluated using the Brief Social Phobia Scale (BSPS). Three hundred forty-six subjects were randomized to 12-13 weeks of treatment with sertraline and 273 subjects to placebo. Following treatment, significant improvement was noted in favor of sertraline on the full BSPS (P<.001), as well as on each of the individual BSPS subscales: fear (P=.001); avoidance (P<.0001); and physiological arousal (P<.0001). Of the physiological symptoms assessed, the treatment advantage with sertraline was maintained for blushing (P<.003) and palpitations (P<.03), but not for trembling and sweating. These results confirm the efficacy of treatment with a selective serotonin reuptake inhibitor (SSRI), sertraline, across the spectrum of fear, avoidance, and physiological arousal in generalized SAD (GSAD). Among common physiological symptoms in this population, blushing and palpitations appear more treatment responsive than trembling and sweating to acute treatment with sertraline.

KW - Blushing

KW - Hyperhidrosis

KW - Phobic disorders

KW - Randomized controlled trial

KW - Serotonin reuptake inhibitors

KW - Sertraline

KW - Social anxiety disorder

UR - http://www.scopus.com/inward/record.url?scp=33644557397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644557397&partnerID=8YFLogxK

U2 - 10.1002/da.20086

DO - 10.1002/da.20086

M3 - Article

C2 - 16216019

AN - SCOPUS:33644557397

VL - 23

SP - 6

EP - 10

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 1

ER -